A new technique for 3D printing medication has enabled the printing of multiple drugs in a single tablet, paving the way for personalised pills that can deliver timed doses. Researchers from the ...
– Phase 3 Results from ARTISTRY-1 and 2 Trials will Form the Basis of Regulatory Submissions – Gilead Sciences, Inc. (NASDAQ: GILD) today announced positive topline results from the Phase 3 ARTISTRY-1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback